January 18, 2024 06:22 AM ESTUpdated 06:35 AM
FDA+
Manufacturing

Sat­suma's nasal mi­graine can­di­date re­ject­ed by FDA over CMC is­sues 

Anna Brown

News Reporter

Sat­suma Phar­ma­ceu­ti­cals was hand­ed a com­plete re­sponse let­ter for its nasal mi­graine drug af­ter the agency found is­sues with the prod­uct’ …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times